Sheet 1 of 5

MODIFIED FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.: NMT-8440

SERIAL No. 10/716,929

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

APPLICANT(S): Rekha Bansal FILING DATE: November 19, 2003

GROUP: 1644

NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/PV/	Α	Acioli, J.M., M. Isobe, and S. Kawasaki, "Early Complement System Activation and Neutrophil priming in acute pancreatitis: Participation of trypsin", Surgery 1997. 122(5) pp. 909-917	
	B	Arnaout, M.A., "Structure and function of the leukocyte adhesion molecules CD11/CD18". Blood, 1990. 1/5(5): p. 1037-50	Ļ
/PV/	С	Barnum, S.R., et al., "Expression of the complement C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma". Am J Respir Crit Care Med, 2001. 164(10 Pt 1): 1841-3.	
/PV/	D	Basta, M., I. Illa, and M.C. Dalakas, "Increased in vitro uptake of the complement C3b in the serum of patients with Culliain-Barre syndrome, myasthenia gravis and dermatomyositis". J Neuroimmunoi, 1996. 71(1-2): p. 227-9.	
/PV/	Е	Bellander, B.M., et al., "Complement activation in the human brain after traumatic head injury". J Neutrotrauma, 2001. 18(12): p. 1295-311. ABSTRACT ONLY	
/PV/	F	Belmont, H.M., et al., "Complement activation during systematic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum, 1986, 29(9): p. 1085-9.	
/PV/	G	Bonser, R.S., et al., "Complement activation before, during and after cardiopulmonary bypass". Eur J Cardiothorac Surg, 1990. 4(6): p. 291-6 ABSTRACT ONLY	
/PV/	Н	Chenoweth, D.E., "Anaphylatoxin formation in extracorporeal circuits", Complement, 1986. 3(3): p. 152-65. ABSTRACT ONLY	
/PV/	I	Davis, E.A., et al., "Inhibition of neutrophil adhesion and the membrane attack complex of complement synergistically prolongs cardiac xenograft survival", J Heart Lung Transplant, 1997, 180 p. 0.774, 0.	
/PV/	J	del Baizo, U., M.J. Polley, and R. Levi, "Cardiac anaphylaxis. Complement activation as an amplification system". Circ Res, 1989. 65(3):p.847-57.	
	K	Fung, M., et al., Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal	L
/PV/	L	Furman, M.I., et al., C/rculating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol, 2001. 38(4): p. 1002-6.	
/PV/	М	Furman, M.I., et al., Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol, 1998. 31(2): p. 352-8.	
/PV/	N	Gerard, N.P. and C. Gerard, Complement in allergy and asthma. Curr Opin Immunol, 2002. 14(6): p. 705-8.	
/PV/	0	Gillinov, A.M., et al., Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg, 1993. 55(3): p. 619-24. ABSTRACT ONLY	
/PV/	Р	Gloor, B., et al., Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis. Scand J Gastroenterol, 2003. 38(10): RSTRACT ONLY	
/PV/	Q	Gong, J., et al., Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol, 1996. 16(4): p. 222-9. ABSTRACT ONLY	
EXAM	INER	DATE CONSIDERED	Γ

G

a

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \$609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED
FORM PTO-1449
(REV. 6-89)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ATTY DOCKET NO.: NMT-8440

SERIAL NO. 10/716.929

APPLICANT(S): Rekha Bansal

FILING DATE: November 19, 2003

GROUP: 1644

NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Grant, E.P., et al., Essential role for the C5a receptor in regulating the effector phase of synovial infiltration	
	- ''	and joint destruction in experimental arthritis. J Exp Med, 2002. 196 (11): p. 1461-71.	
		Grossklaus, C., et al., Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunyn Schmiedebergs Arch Pharmacol, 1976. 295(1): p. 71-6.	
	С	Gupta-Bansal, R., J.B. Parent, and K.R. Brunden, Inhibition of complement alternative pathway function	
		With and proper an information and an arrangement with an arrangement and arrangement are arra	
/PV/	D	Haeffner-Cavaillon, N., et al., C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol, 1987. 139(3): p. 794-9.	
/PV/	E	Holmes, J.H.t., et al., Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res, 2002. 51(12): p. 579-86. ABSTRACT ONLY	
/PV/	F	Hopkins, P., et al., Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum, 1988. 31(5): p. 632- 41. ABSTRACT ONLY	
/PV/	G	Horigome, I., et al., <i>Terminal complement complex in plasma from patients with systemic lupus</i> erythematosus and other glomerular diseases. Clin Exp Immunol, 1987. 70 (2): p. 417-24.	
/PV/	Н	Howard, R.J., et al., Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation. Arch Surg, 1988. 123 (12): p. 1496-501. ABSTRACT ONLY	
/PV/	ı	Humbles, A.A., et al., A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature, 2000. 406(6799): p. 998-1001.	
/PV/	J	Johnson, L.V., et al., Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res, 2001. 73(6): p. 887-96. ABSTRACT ONLY	
/PV/	к	Kaczorowski, S.L., et al., Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab, 1995. 15(5): p. 860-4. ABSTRACT ONLY	
/PV/	L	Kirschfink, M., et al., [Significance of the complement system for xenotransplantation: strategies for therapeutic intervention]. Zentralbl Chir, 1998. 123(7): p. 793-7. ABSTRACT ONLY	
/PV/	М	Krug, N., et al., Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med, 2001. 164(10 Pt 1): p. 1841-3.	
/PV/	N	Langlois, P.F. and M.S. Gawryl, Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis, 1988. 70(1-2): p. 95-105. ABSTRACT ONLY	
/PV/	0	Lien, Y.H., L.W. Lai, and A.L. Silva, Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci, 2003. 74 (5): p. 543-52.	
/PV/	Р	Lin F. et al., Decay-Accelerating Factor Deficiency Increases Susceptibility to Dextran Sulfate Sodium- Induced Colitis: Role for Complement in Inflammatory Bowel Disease, Journal of Immunology 2004, 172:3836-3841	
/PV/	Q	Mead, R.J., et al., The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol, 2002. 168 (1): p. 458-65. ABSTRACT ONLY	
-V.	INIED.	DATE CONCIDENCE	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.: NMT-8440

FILING DATE: November 19, 2003

SERIAL NO. 10/716.929

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

APPLICANT(S): Rekha Bansal

GROUP: 1644

NON-PATENT LITERATURE DOCUMENTS (Including Author Title Date Pertinent Pages Etc.)

	NON	-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/PV/	Α	Meuer, S., et al., Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol, 1981. 126(4): p. 1506-9. ABSTRACT ONLY		
/PV/	В	Mohr, R., et al., The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg, 1988. 96(4): p. 530-4. ABSTRACT ONLY		
/PV/	С	Mullins, R.F., N. Aptsiauri, and G.S. Hageman, Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye, 2001. 15(Pt 3): p. 390-5. ABSTRACT ONLY		
/PV/	D	Nataf, S., et al., Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol, 2000. 165(10): p. 5867-73. ABSTRACT ONLY		
/PV/	E	Pruitt, S.K., et al., The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation, 1994. 57(3): p. 363-70. ABSTRACT ONLY		
/PV/	E	Rinder, C.S., et al., Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood, 1992. 79 (5): p. 1201-5. ABSTRACT ONLY		
/PV/	G	Rinder, C.S., et al., Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation, 1999. 100(5): p. 553-8. ABSTRACT ONLY		
/PV/	T	Rinder, C.S., et al., Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest, 1995. 96(3): p. 1564-72.		
/PV/	1	Roxvall, L., A. Bengtson, and M. Heideman, <i>Anaphylatoxin generation in acute pancreatitis</i> . J Surg Res, 1989. 47(2): p. 138-43. ABSTRACT ONLY		
/PV/	J	Roxvall, L.I., L.A. Bengtson, and J.M. Heideman, Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and assites fluid of patients with acute pancreatitis. Arch Surg, 1990. 125(7), p.918-21. ABSTRACT ONLY		
/PV/	К	Saarvedt, K., et al., Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulnonary bypass in children. Scand J Clin Lab Invest, 1995. 55(1): p. 7–95.6. ABSTRACT ONLY		
/PV/	L	Schmid, E., et al., Requirement for C5a in lung vascular injury following thermal trauma to rat skin. Shock, 1997. 8(2): p. 119-24. ABSTRACT ONLY		
/PV/	1	Simpson, P.J., et al., Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest, 1983, 81(2), P.T. 2011.		
/PV/	N	Stahel, P.F., M.C. Morganti-Kossmann, and T. Kossmann, <i>The role of the complement system in traumatic brain injury</i> . Brain Res Brain Res Rev, 1998. 27 (3): p. 243-56. ABSTRACT ONLY		
/PV/	ĕ	Stahl, G.L., et al., Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol, 2003. 162(2): p. 449-55. ABSTRACT ONLY		
/PV/	Р	Thurman, J.M., et al., Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol, 2003. 170(3): p. 1517-23. ABSTRACT ONLY		
/PV/	Q	Torzewski, J., et al., Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol, 1996. 16		
EXAM	INER	DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIF FORM P (REV. 6-	TO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.: NMT-8440	SERIAL NO. 10/716,929
		RMATION DISCLOSURE EMENT BY APPLICANT	APPLICANT(S): Rekha Bansal	
	(Use sei	veral sheets if necessary)	FILING DATE: November 19, 2003	GROUP: 1644
	NON-	PATENT LITERATURE DOCUME	NTS (Including Author, Title, Date, F	Pertinent Pages, Etc.)
/PV/	Α		r D monoclonal antibody inhibits compo nonary bypass. Ann Thorac Surg, 2002.	
/PV/	В	van Beek, J., K. Elward, and P. C in neurodegeneration and neurop	Basque, <i>Activation of complement in th</i> protection. Ann N Y Acad Sci, 2003. 99	e central nervous system: roles 2: p. 56-71. ABSTRACT ONLY
/PV/	С	Vedeler, C.A., et al., Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barre syndrome and multiple sclerosis. J Neuroimmunol, 1996. 67(1): p. 17-20. ABSTRACT 0		
/PV/	D	Vickers, J., et al., Measurement of platelet activation and adhesion to leukocytes during haemodialysis. Platelets, 1998. 9(3-4): p. 261-4. ABSTRACT ONLY		
/PV/	E	Wan, K.C., et al., <i>A longitudinal s</i> Burns, 1998. 24 (3): p. 241-4.	study of C3, C3d and factor Ba in burn	patients in Hong Kong Chinese.
/PV/	F	Wang, Y., et al., Anti-C5 monocle ameliorates established disease.	onal antibody therapy prevents collage. Proc Natl Acad Sci U S A, 1995. 92 (19	n-induced arthritis and 9): p. 8955-9.
PV/	G	Ware, L.B. and M.A. Matthay, <i>Th</i> p. 1334-49.	e acute respiratory distress syndrome.	N Engl J Med, 2000. 342 (18):
PV/	Н	Yasuda, M., et al., The complement system in ischemic heart disease. Circulation, 1990. 81(1): p. 156-63. ABSTRACT ONLY		
/PV/	1	Zhou, W., et al., Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest, 2000. 105(10): p. 1363-71.		
/PV/	J		e impairment and driving performance , 2003. 23 (3): p. 334-40. ABSTRACT	
	К	Ann Thorac Surg. 1994 Mar;57(3	i):781-3, P.C. a.a.C. a.c.d.c.h.M.P., Che	llo M, Marchese AR.)
		Arrowsmith, J.E., et al., <i>Central r</i> 84(3): p. 378-93.	nervous system complications of cardia	c surgery. Br J Anaesth, 2000.
/PV/	М	Cecic, I., J. Sun, and M. Korbelik	, Role of complement anaphylatoxin C rophils and other immune cells. Photoc	
PV/	N		toperative cognitive change after cardio . 411-21.	opulmonary bypass surgery.
		resembling those in a cardiopuln	omplement activation by soluble recom nonary circuit: reduced up-regulation of	CD11b and complete
		abrogation of binding of PMNs to 27.	the biomaterial surface. Immunopham	nacology, 1997. 38(1-2): p. 119-
/PV/	Р	Levy, J.H. and K.A. Tanaka, Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg, 2003. 75(2): p. S715-20.		
PV/	Q	Mahanna, E.P., et al., <i>Defining neuropsychological dysfunction after coronary artery bypass grafting</i> . Ann Thorac Surg, 1996. 61(5): p. 1342-7.		
	NER	•	DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

MODIFIED	
FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE
(REV. 6-89)	PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.: NMT-8440

SERIAL NO. 10/716,929

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

APPLICANT(S): Rekha Bansal

GROUP: 1644

FILING DATE: November 19, 2003 GR

	NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/PV/	А	Neumann, E., et al., Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum, 2002. 46 (4): p. 934-45. ABSTRACT ONLY	
/PV/	В	Newman, M.F., Kirchner J.L., Phillips-Bute B., Longitudinal assessment of neurocognitive function after cornary artery bypass surgery. N Engl J Med, 2001. 344: p. 395-402.	
		Nilsson B, L.R., Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD., Compstatin inhibits complement	
		1;92(5):1661-7.	
/PV/	D	Finder, C.S., et al., Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg, 1999. 118(3): p. 460-6.	
/PV/	E Selnes, O.A. and G.M. McKhann, Neurocognitive complications after coronary artery bypass surgery. Ann Neurol, 2005. 57(5): p. 615-21. ABSTRACT ONLY		
	——F	Selnes, O.A., et al., Cognitive and neurobehavioral dysfunction after cardiac bypass procedures. Neurol Clin, 2006. 24 (1): p. 133-45.	
	G		
	Н		
	1		
	J		
	к		
	L		
	М		
	N		
	0		
	Р		
	Q		
EXAM	INER /F	Pierre Vandervegt/ DATE CONSIDERED 03/28/2008	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.